These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29416738)

  • 1. PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation.
    Yin ZX; Hang W; Liu G; Wang YS; Shen XF; Sun QH; Li DD; Jian YP; Zhang YH; Quan CS; Zeng Q; Li YL; Zhao RX; Ding Q; Xu ZX
    Oncotarget; 2018 Jan; 9(2):1885-1897. PubMed ID: 29416738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1.
    Hang W; Yin ZX; Liu G; Zeng Q; Shen XF; Sun QH; Li DD; Jian YP; Zhang YH; Wang YS; Quan CS; Zhao RX; Li YL; Xu ZX
    Oncogene; 2018 Jun; 37(25):3384-3398. PubMed ID: 29348462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
    Deben C; Lardon F; Wouters A; Op de Beeck K; Van den Bossche J; Jacobs J; Van Der Steen N; Peeters M; Rolfo C; Deschoolmeester V; Pauwels P
    Cancer Lett; 2016 Jun; 375(2):313-322. PubMed ID: 26975633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.
    Peng X; Zhang MQ; Conserva F; Hosny G; Selivanova G; Bykov VJ; Arnér ES; Wiman KG
    Cell Death Dis; 2013 Oct; 4(10):e881. PubMed ID: 24157875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
    Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
    Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy.
    Bykov VJ; Zhang Q; Zhang M; Ceder S; Abrahmsen L; Wiman KG
    Front Oncol; 2016; 6():21. PubMed ID: 26870698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments.
    de Bakker T; Journe F; Descamps G; Saussez S; Dragan T; Ghanem G; Krayem M; Van Gestel D
    Front Oncol; 2021; 11():799993. PubMed ID: 35071005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma.
    Caicedo-Granados E; Lin R; Fujisawa C; Yueh B; Sangwan V; Saluja A
    Oral Oncol; 2014 Dec; 50(12):1149-56. PubMed ID: 25311433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Oxidative Stress With Auranofin or Prima-1
    Tessoulin B; Descamps G; Dousset C; Amiot M; Pellat-Deceunynck C
    Front Oncol; 2019; 9():128. PubMed ID: 30895171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
    Li C; Johnson DE
    Cell Cycle; 2013 Mar; 12(6):923-34. PubMed ID: 23421999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of PARP inhibition in enhancing the radiosensitivity of 3D spheroids of head and neck squamous cell carcinoma.
    Zhou C; Fabbrizi MR; Hughes JR; Grundy GJ; Parsons JL
    Front Oncol; 2022; 12():940377. PubMed ID: 36052247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models.
    Hernandez AL; Young CD; Bian L; Weigel K; Nolan K; Frederick B; Han G; He G; Devon Trahan G; Rudolph MC; Jones KL; Oweida AJ; Karam SD; Raben D; Wang XJ
    Clin Cancer Res; 2020 Jun; 26(12):3058-3070. PubMed ID: 32139402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
    Osman AA; Monroe MM; Ortega Alves MV; Patel AA; Katsonis P; Fitzgerald AL; Neskey DM; Frederick MJ; Woo SH; Caulin C; Hsu TK; McDonald TO; Kimmel M; Meyn RE; Lichtarge O; Myers JN
    Mol Cancer Ther; 2015 Feb; 14(2):608-19. PubMed ID: 25504633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.
    Freire Boullosa L; Van Loenhout J; Flieswasser T; Hermans C; Merlin C; Lau HW; Marcq E; Verschuuren M; De Vos WH; Lardon F; Smits ELJ; Deben C
    Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA.
    Hedström E; Eriksson S; Zawacka-Pankau J; Arnér ES; Selivanova G
    Cell Cycle; 2009 Nov; 8(21):3584-91. PubMed ID: 19838062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation.
    Kobayashi T; Makino T; Yamashita K; Saito T; Tanaka K; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Morii E; Eguchi H; Doki Y
    Br J Cancer; 2021 Nov; 125(11):1523-1532. PubMed ID: 34599296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitrovin (difurazone), an antibacterial growth promoter, induces ROS-mediated paraptosis-like cell death by targeting thioredoxin reductase 1 (TrxR1).
    Zhao L; Zhong B; Zhu Y; Zheng H; Wang X; Hou Y; Lu JJ; Ai N; Guo X; Ge W; Ma YY; Chen X
    Biochem Pharmacol; 2023 Apr; 210():115487. PubMed ID: 36893814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines.
    Güster JD; Weissleder SV; Busch CJ; Kriegs M; Petersen C; Knecht R; Dikomey E; Rieckmann T
    Radiother Oncol; 2014 Dec; 113(3):345-51. PubMed ID: 25467050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
    Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
    Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.